Abstract
The development of perospirone was initiated by Sumitomo Pharmaceuticals based on research on tandospirone, which is an azapirone anxiolytic, and perospirone was approved in Japan in December 2000. Meanwhile, blonanserin was synthesized and developed on the basis of the atypical theory of serotonin–dopamine antagonists (SDAs), which was a method already established by Dainippon Pharmaceutical at that time; blonanserin was approved in Japan in January 2008. Lurasidone was based on tandospirone as well; after the merger of the two companies, Sumitomo Dainippon Pharma conducted a phase 3 clinical trial, and after US approval in 2011, it was developed in Japan to obtain approval in March 2020. The common characteristics of these three drugs are their selective binding profiles for targeting multiple receptors (conversely, they are not designed to bind to non-target targets), their efficacy as atypical antipsychotics, and their effective application as SDA therapies with low safety risks (such as excessive sedation). Later scientific advances revealed the affinity of dopamine and serotonin receptors to subtypes (dopamine D3 and serotonin 5-HT7 receptors) that is possible to characterize the effects of each drug. Their clinical effects, which are presumed to occur through their agonistic/antagonistic action on the receptors, contribute to the advances in antipsychotic-based pharmacotherapy for schizophrenia and bipolar disorder.
This is a preview of subscription content, log in via an institution to check access.
References
Higuchi T, Ishigooka J, Iyo M, Yeh CB, Ebenezer EG, Liang KY, et al. Lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in Asian patients. Asia Pac Psychiatry. 2019a;11(2):e12352.
Higuchi T, Iyo M, Kwon JS, Chou YH, Chen HK, Chen JY, et al. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: results of an inconclusive 6-week trial. Asia Pac Psychiatry. 2019b;11(3):e12354.
Iwata N, Ishigooka J, Kim W-H, Yoon B-H, Lin S-K, Sulaiman AH, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2020;215:408–15.
Kato T, Ishigooka J, Miyajima M, Watanabe K, Fujimori T, Masuda T, et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci. 2020; https://doi.org/10.1111/pcn.13137.
Kudo Y, Nakajima T, Saito M, Sakai T, Otsuki S, Yamawaki S, et al. Clinical evaluation of a serotonin-2 and dopamine-2 antagonist (SDA), perospirone HCl on schizophrenia. A comparative double-blind study with mosapramine HCl. Clin Eval. 1997;24:207–48. (in Japanese, abstract in English).
Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–9.
Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014a;171(2):160–8.
Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014b;171(2):169–77.
Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3(2):64–75.
Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–67.
Miura S. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol. 2008;11:297–314. (in Japanese, abstract in English).
Murasaki M. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharacol. 2007;10:2059–79. (in Japanese, abstract in English).
Murasaki M, Koyama T, Machiyama Y, Yagi G, Kamijima K, Toru M, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia – a comparative double-blind study with haloperidol. Clin Eval. 1997;24:159–205. (in Japanese, abstract in English).
Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–7.
Sumitomo Dainippon Pharma Co., Ltd. (in Japanese). Lullan (perospirone) [interview form], vol. 22. 2020a. https://ds-pharma.jp/product/lullan/attachment/interv.html. Accessed 8 Jan 2021.
Sumitomo Dainippon Pharma Co., Ltd. (in Japanese). LONASEN tablets/powders (blonanserin) [interview form], vol. 18. 2020b. https://ds-pharma.jp/product/lonasen/attachment/interv.html. Accessed 8 Jan 2021.
Sumitomo Dainippon Pharma Co., Ltd. (in Japanese). LONASEN tapes (blonanserin) [interview form], vol. 6. 2020c. https://ds-pharma.jp/product/lonasentape/attachment/interv.html. Accessed 8 Jan 2021.
Sumitomo Dainippon Pharma Co., Ltd. (in Japanese). Latuda (lurasidone) [interview form], vol. 4. 2020d. https://ds-pharma.jp/product/latuda/attachment/interv.html. Accessed 8 Jan 2021.
Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:86–93.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond D, Frey BN, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Inada, K., Ishigooka, J., Murasaki, M. (2021). From Perospirone and Blonanserin to Lurasidone. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_429-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_429-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine